Alzther Industries (ISIN: KR7119857621) a start-up biotechnology company, focused on diseases associated with protein misfolding and which is developing drugs to halt the progression of Alzheimer’s disease and companion diagnostics for the early detection of Alzheimer’s disease, today announced that the results from the project in cooperation with a renowned Research Laboratories using a commercial microarray platform confirm that Alzther Industries` method can be used to detect Alzheimer`s disease.
The study has now been continued in a comprehensive project at the external service laboratory in US, using a commercial microarray platform. The first analytical work on this larger study has now been completed and the project has been confirmed as a success. George Lee Tak, Director of Technology at Alzther Industries, comments in connection with the future publication of the results: “The first results from this comprehensive project confirm that Alzther Industries` method can be used to detect Alzheimer`s disease.”
Alzther Industries cooperates with the American Association for Biosciences (AAB) in connection with the regulated projects underwent by this respected entity. AAB has considerable experience in the analysis of microarray data. Kate Birmingham, Professor of Neuro Medicine at AAB, comments: “The results from the Alzheimer`s study support Alzther Industries` concept. The results obtained were based on a large number of samples, and recognised statistical methods were used in analysis and validation of the results.”
In recent months Alzther Industries has recorded increased international acceptance of the diagnostic concept involving the use of blood as a sample material combined with analysis of gene expression. Particularly for conditions such as Alzheimer`s disease and other diseases of the brain and nervous system it is in practice impossible to use sample material from the site of the disease. A number of scientific articles by external researchers also support this concept.

[b]About Alzther Industries (ISIN: KR7119857621)[/b]

Alzther Industries is a start-up biotechnology company supported by various grants and private investors. The funds and our investors support projects with a high potential for future innovations. Alzther Industries is focused on diseases associated with protein misfolding. The company is currently developing drugs to halt the progression of Alzheimer’s disease and companion diagnostics for the early detection of Alzheimer’s disease. Alzther Industries is focused on drug development until phase II clinical studies. The location of the company in Seoul enables the access to experienced experts in the field of drug discovery and development, as well as business development and commercialization.